Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.
2.

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.

Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV.

Hum Psychopharmacol. 2005 Jul;20(5):327-41. Review.

PMID:
15912562
3.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
4.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
6.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
7.

Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.

Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, Walicke PA, Gottlieb AB.

J Cutan Med Surg. 2005 Dec;9(6):313-23. Review.

PMID:
16699903
8.

The clinical tolerability profile of alendronate.

Watts N, Freedholm D, Daifotis A.

Int J Clin Pract Suppl. 1999 Apr;101:51-61. Review.

PMID:
12669741
9.

Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects.

Rief W, Avorn J, Barsky AJ.

Arch Intern Med. 2006 Jan 23;166(2):155-60. Review.

PMID:
16432082
10.
11.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

12.

What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports.

Frank S, Kieburtz K, Holloway R, Kim SY.

Neurology. 2005 Oct 11;65(7):1101-3. Epub 2005 Jul 20. Review.

PMID:
16033990
13.

Placebo--the forgotten drug.

Boström H.

Scand J Work Environ Health. 1997;23 Suppl 3:53-7. Review.

14.

Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful.

Parasrampuria DA, Benet LZ.

Basic Clin Pharmacol Toxicol. 2015 Jul;117(1):44-51. doi: 10.1111/bcpt.12352. Epub 2014 Dec 23. Review.

15.

[Variability in the placebo values].

Rybicka J.

Pol Arch Med Wewn. 2003 Jun;109(6):657-60. Review. Polish. No abstract available.

PMID:
14567100
Items per page

Supplemental Content

Write to the Help Desk